Delighted to see ONK Therapeutics feature in the NK cell therapy company review by Labiotech.eu. Great to see our teams efforts recognized as we continue to explore our innovative gene editing strategy and explore the versatility of our highly functional NK cells, including in combination with NK cell engagers through our evolving partnership with NAYA Biosciences. #cancer #oncology #immunotherapy #editing #crispr #NKcells https://lnkd.in/dSTFKgVt
ONK Therapeutics
Biotechnology Research
Pioneering optimally engineered NK cell therapies to cure patients with cancer.
About us
ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies and solid tumors. The Company was founded in 2015, by Prof. O’Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.
- Website
-
http://www.onktherapeutics.com
External link for ONK Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Galway
- Type
- Privately Held
- Founded
- 2015
Locations
-
Primary
Get directions
Galway, IE
Employees at ONK Therapeutics
Updates
-
We are excited to announce our research partnership with NAYA Biosciences to advance combination therapy of our optimally engineered off-the-shelf therapies with its FLEX-NK™ bispecific antibodies. Working together, our R&D teams will assess combination therapies in preclinical cancer models. Our studies will involve evaluating several of ONK gene-edited NK cell therapies that harness different combinations of gene edits, including CISH knock-out (KO), TGFβR2 KO, CD38 KO, and IL15 knock-in (KI) with NAYA’s FLEX-NK engagers, prior to selecting the best candidates for continued development. Read more: https://lnkd.in/d7fzWk5Q #cancer #oncology #immunotherapy #editing #crispr #NKcells #autoimmunedisease
-
-
Today, on #WorldCordBloodDay we’re applauding how cord blood is transforming the lives of many patients with 80+ life-threatening diseases including #leukemia, #lymphoma, and #thalassemia. The first cord blood stem cell transplant occurred almost 45 years ago. Now, thanks to generous donors, cord blood is utilized both as a direct treatment and as a source of cord-derived cells including Natural Killer (NK) cells. At ONK Therapeutics we are using a suite of gene-editing tools and strategies to optimally engineer NK cell therapies and create differentiated products for patients with hematological malignancies and solid tumors. We’re grateful to Anthony Nolan: Cell Therapy and Laboratory Services for the umbilical cord-derived #NK-cells, which provide a consistent, ethically sourced supply of the starting material for our pioneering R&D programs. Learn more about #WorldCordBloodDay: https://lnkd.in/euRj_Yg #WCBD23 #immunotherapy #CARNK #CellTherapy #cancer #oncology #lifesciences #cellandgenetherapy
-
-
We are delighted to announce that the European Patent Office (EPO) has granted ONK Therapeutics’ foundational patent for CISH knockout (KO) in Natural Killer (#NK) cells. This follows the grant of the patent in the USA by USPTO and in Japan by Japan Patent Office (JPO). The patent, under exclusive global license from WEHI (Walter and Eliza Hall Institute of Medical Research) gives us the key IP for CISH KO in human NK cells for their use in cancer therapies, irrespective of cell origin. Cytokine Inducible SH2-containing protein (CIS; encoded by the gene CISH) is a potent checkpoint in NK cell-mediated tumor immunity. CISH KO NK cells have been shown to be more efficient in eliminating cancer cells in in-vivo models. This CISH IP adds to ONK’s broad and growing IP estate covering the optimization of persistence, metabolic profile and cytotoxic potential of our NK cell therapy platform. https://lnkd.in/dftJ_PFc #CISH #CARNK #CellTherapy #TRAILv #NK-cells #cancer #oncology #immunotherapy #cellandgenetherapy
-